LINC-PINT, a long intergenic non-coding RNA triggered by p53, inhibits tumor cell proliferation in glioblastoma, hepatocellular carcinoma, and laryngeal squamous cell carcinoma (LSCC), making it a potential therapeutic target for tumor treatment [29–31]. This evidence concerns the gene LINC-PINT and hepatocellular carcinoma.